Cancer Drug's Real-World performance under the microscope

NCT ID NCT06873191

Not yet recruiting Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

Summary

This study aims to monitor the safety and effectiveness of the breast cancer drug TUKYSA in real-world medical practice in Korea. It will enroll 600 adults with advanced HER2-positive breast cancer who are starting TUKYSA treatment as prescribed by their doctor. The main goal is to collect information on side effects and how well the drug works in everyday use, following patients for up to one year.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.